#1 prescribed treatment for
Huntington's disease (HD) chorea*

*Time period 05/2022 through 07/2024.
AUS-47394 September 2024

for HD Chorea in Adults

Greater than 2X Reduction.

in uncontrolled movements vs placebo at 12 weeks

See study results

4.4-point improvement in people taking AUSTEDO vs 1.9 in people taking placebo based on Total Maximal Chorea (TMC) score. The TMC score is used to measure Huntington’s disease (HD) chorea movements in the face, mouth, trunk, both arms, and both legs.1,2

Eligible patients may pay as little as $ per month
Discover the benefits

Offer is only available to patients with commercial insurance. Offer is NOT available to patients eligible for Medicare, Medicaid, or any other government payer coverage. Out-of-pocket costs may vary. Exclusions and limitations apply. Please see complete Terms and Conditions.

References:

1. AUSTEDO® XR (deutetrabenazine) extended-release tablets/AUSTEDO® tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.

2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.